Uno Konomu, Nishie Hirotada, Hiyoshi Hiromi, Habu Kyosuke, Nakayama Jun, Tate Sota, Sakaue Tomohisa, Kubota Eiji, Tanaka Mamoru, Shimura Takaya, Kataoka Hiromi, Joh Takashi, Higashiyama Shigeki
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Japan.
Cancer Sci. 2025 Sep;116(9):2580-2591. doi: 10.1111/cas.70107. Epub 2025 Jun 12.
The KLHL gene family member KLHL5, which is a constituent factor of the RING E3 ubiquitin ligase complex, is expressed in various types of cancers and plays a role in cancer pathophysiology. In this study, we identified KLHL5 as a potential biomarker for predicting the prognosis of colorectal cancer (CRC) from 42 KLHL family genes using transcriptome profiles generated by RNA-seq analysis of The Cancer Genome Atlas colorectal adenocarcinoma (TCGA-COAD). We further investigated the implication of KLHL5 in CRC using pathological examination and bioinformatics analyses. Clinicopathological analyses revealed that KLHL5 was more highly expressed in CRC than in adjacent normal mucosa, and its expression level increased concomitantly with the CRC stage (p < 0.05). KLHL5 expression was associated with poor prognostic factors such as depth of invasion (p < 0.001), lymphovascular invasion (p = 0.029), and lymph node metastasis (p = 0.025). Notably, KLHL5 exhibited heterogeneous expression within the tumor, with pronounced expression observed at the invasive front of the tumor (p < 0.0001). Through bioinformatics analyses, we determined that elevated KLHL5 expression in CRC is significantly associated with poor prognosis. Furthermore, analysis from the Gene Expression Omnibus database indicated that KLHL5 expression was more pronounced in the common molecular subtype (CMS) 4 CRC, which is characterized as highly advanced, and the overall and recurrence-free survival rates were poor compared to other CMS groups. Our findings indicate that KLHL5 plays a pivotal role in the progression and development of CRC, and can be used as a potential biomarker and therapeutic target for CRC treatment.
KLHL基因家族成员KLHL5是环状E3泛素连接酶复合物的组成因子,在多种癌症类型中表达,并在癌症病理生理学中发挥作用。在本研究中,我们利用癌症基因组图谱结直肠癌(TCGA-COAD)的RNA测序分析生成的转录组谱,从42个KLHL家族基因中鉴定出KLHL5作为预测结直肠癌(CRC)预后的潜在生物标志物。我们进一步通过病理检查和生物信息学分析研究了KLHL5在CRC中的意义。临床病理分析显示,KLHL5在CRC中的表达高于相邻正常黏膜,其表达水平随CRC分期而升高(p<0.05)。KLHL5表达与侵袭深度(p<0.001)、淋巴管侵袭(p=0.029)和淋巴结转移(p=0.025)等不良预后因素相关。值得注意的是,KLHL5在肿瘤内表现出异质性表达,在肿瘤侵袭前沿观察到明显表达(p<0.0001)。通过生物信息学分析,我们确定CRC中KLHL5表达升高与不良预后显著相关。此外,基因表达综合数据库的分析表明,KLHL5在常见分子亚型(CMS)4 CRC中表达更明显,该亚型特征为高度进展,与其他CMS组相比,总生存率和无复发生存率较差。我们的研究结果表明,KLHL5在CRC的进展和发展中起关键作用,可作为CRC治疗的潜在生物标志物和治疗靶点。